Journal
CURRENT ALLERGY AND ASTHMA REPORTS
Volume 12, Issue 3, Pages 246-254Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11882-012-0256-5
Keywords
Multiple sclerosis; Treatment; Algorithm; Interferon-beta; Glatiramer acetate; Natalizumab; Mitoxantrone; Fingolimod; Dimethyl fumarate; Cladribine; Alemtuzumab; Rituximab
Categories
Funding
- Biogen Idec
- Novartis
Ask authors/readers for more resources
Multiple sclerosis is the most common cause of disability in young people in the Western world. Reduced life expectancy and worsening quality of life due to increasing disability later in the disease course have significant personal and societal costs. Changes in treatment strategies and newly available treatments hope to improve the outlook for our often young patients. This paper details currently available treatments and some that are expected to reach the market shortly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
